Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

Alison Rodger(University College London), Valentina Cambiano(University College London), Tina Bruun(University of Copenhagen), Pietro Vernazza(Kantonsspital St. Gallen), Simon Collins, Olaf Degen(Universität Hamburg), Giulio Maria Corbelli(European Organisation for Research and Treatment of Cancer), Vicente Estrada(Hospital Clínico San Carlos), Anna María Geretti(University of Liverpool), Apostolos Beloukas(University of Liverpool), Dorthe Raben(University of Copenhagen), Pep Coll(IrsiCaixa), Andrea Antinori(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Nneka Nwokolo(Chelsea and Westminster Hospital NHS Foundation Trust), Armin Rieger(Medical University of Vienna), Jan M. Prins(Amsterdam University Medical Centers), Anders Blaxhult(Stockholm South General Hospital), Rainer Weber(University of Zurich), Arne van Eeden(Dutch Cancer Society), Norbert H. Brockmeyer(Ruhr University Bochum), Amanda Clarke(Brighton and Sussex Medical School), Jorge del Romero Guerrero, F. Raffi(Inserm), Johannes R. Bogner(LMU Klinikum), Gilles Wandeler(University of Bern), Jan Gerstoft(Rigshospitalet), Félix Gutiérrez(Universitat de Miguel Hernández d'Elx), Kees Brinkman(OLVG), Maria Kitchen(Innsbruck Medical University), Lars Ostergaard(Aarhus University Hospital), Agathe León(Hospital Clínic de Barcelona), Matti Ristola(University of Helsinki), Heiko Jessen(Orthopädische Praxis), Hans‐Jürgen Stellbrink(Infektionsmedizinisches Centrum Hamburg), Andrew Phillips(University College London), Jens Lundgren(University of Copenhagen), Pep Coll(IrsiCaixa), Patricia Cobarsí, Aroa Nieto, Michael Meulbroek, Antonia Carrillo, Jorge Saz, Jorge D.R. Guerrero, Mar Vera García, Félix Gutiérrez(Universitat de Miguel Hernández d'Elx), Mar Masiá(Innsbruck Medical University), Catalina Robledano, Agathe León(Hospital Clínic de Barcelona), Lorna Leal, Eva G. Redondo, Vicente Estrada(Hospital Clínico San Carlos), Rocio Marquez, Raquel Sandoval, Pompeyo Viciana, Núria Espinosa, Luís F. López‐Cortés, Daniel Podzamczer, Juan Tiraboschi, Sandra Morenilla, Antonio Antela, Elena Losada, Nneka Nwokolo(Chelsea and Westminster Hospital NHS Foundation Trust), Janey Sewell, Amanda Clarke(Brighton and Sussex Medical School), S Kirk, Alyson Knott, Alison Rodger(University College London), Thomas Fernandez, Mark Gompels, Louise Jennings, Lana Ward, Julie Fox, Julianne Lwanga, Ming Lee, Richard Gilson, Clifford Leen, Sheila Morris, Dan Clutterbuck, Michael Brady, David Asboe, Serge Fedele, Sarah Fidler, Norbert H. Brockmeyer(Ruhr University Bochum), Anja Potthoff, Adriane Skaletz‐Rorowski, Johannes R. Bogner(LMU Klinikum), Ulrich Seybold, Julia Roider, Heiko Jessen(Orthopädische Praxis), Arne Jessen(Orthopädische Praxis), Slobodan Ruzicic, Hans‐Jürgen Stellbrink(Infektionsmedizinisches Centrum Hamburg), Tim Kümmerle, Clara Lehmann, Olaf Degen(Universität Hamburg), Sindy Bartel, Anja Hüfner, Jürgen K. Rockstroh(Infektionsmedizinisches Centrum Hamburg), Karina Mohrmann, Christoph Boesecke, Ivanka Krznaric, Patrick Ingiliz, Rainer Weber(University of Zurich), Christina Grube, Dominique L. Braun, Huldrych F. Günthard, Gilles Wandeler(University of Bern), Hansjakob Furrer, Andri Rauch, Pietro Vernazza(Kantonsspital St. Gallen), Patrick Schmid, Manuela Rasi, Denise Borso, Markus Stratmann, Oliver Caviezel, Marcel Stoeckle, Manuel Battegay, Philip Tarr, Vanessa Christinet, Florent Jouinot, Camille Isambert, Enos Bernasconi, Beatrice Bernasconi, Jan Gerstoft(Rigshospitalet), Lene Pors Jensen, Anne A. Bayer(LMU Klinikum), Lars Ostergaard(Aarhus University Hospital), Yordanos Yehdego, Ann Bach(LMU Klinikum), Pia Handberg, Gitte Kronborg, Svend s. Pedersen, Nete Bülow, Bente Ramskover, Matti Ristola(University of Helsinki), Outi Debnam, Jussi Sutinen, Anders Blaxhult(Stockholm South General Hospital), Ronnie Ask, Bernt Hildingsson-Lundh, Katarina Westling, Eeva-Maija Frisen, Gráinne Cortney, Siobhán O’Dea, Stéphane De Wit, Coca Necsoi, Linos Vandekerckhove, Jean‐Christophe Goffard, Sophie Henrard, Jan M. Prins(Amsterdam University Medical Centers), Hans-Henrik Nobel, Annouschka M. Weijsenfeld, Arne van Eeden(Dutch Cancer Society), L. Elsenburg, Kees Brinkman(OLVG), Danielle Vos, Imke Hoijenga, Elisabeth H. Gisolf, Petra van Bentum, D.W.M. Verhagen(Inserm), F. Raffi(Inserm), Éric Billaud, Michel Ohayon, Daniel Gosset, Alexandre Fior(University of Bern), Gilles Pialoux, Pélagie Thibaut, Julie Chas, Vincent Leclercq, V Péchenot, Vincent Coquelin, Christian Pradier, S Bréaud, Veronique Touzeau-Romer(Medical University of Vienna), Armin Rieger(Innsbruck Medical University), Maria Geit, Mario Sarcletti, Martin Gisinger, Angela Oellinger(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Andrea Antinori(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Samanta Menichetti, Teresa Bini, Cristina Mussini, Marianna Meschiari, Antonio Di Biagio, Lucia Taramasso, Benedetto Maurizio Celesia(Innsbruck Medical University), Maria Gussio, Nuno Janeiro
The Lancet
May 2, 2019
Cited by 991Open Access
Full Text

Abstract

BACKGROUND: The level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral therapy (ART) is limited compared with the evidence available for transmission risk in heterosexual couples. The aim of the second phase of the PARTNER study (PARTNER2) was to provide precise estimates of transmission risk in gay serodifferent partnerships. METHODS: The PARTNER study was a prospective observational study done at 75 sites in 14 European countries. The first phase of the study (PARTNER1; Sept 15, 2010, to May 31, 2014) recruited and followed up both heterosexual and gay serodifferent couples (HIV-positive partner taking suppressive ART) who reported condomless sex, whereas the PARTNER2 extension (to April 30, 2018) recruited and followed up gay couples only. At study visits, data collection included sexual behaviour questionnaires, HIV testing (HIV-negative partner), and HIV-1 viral load testing (HIV-positive partner). If a seroconversion occurred in the HIV-negative partner, anonymised phylogenetic analysis was done to compare HIV-1 pol and env sequences in both partners to identify linked transmissions. Couple-years of follow-up were eligible for inclusion if condomless sex was reported, use of pre-exposure prophylaxis or post-exposure prophylaxis was not reported by the HIV-negative partner, and the HIV-positive partner was virally suppressed (plasma HIV-1 RNA <200 copies per mL) at the most recent visit (within the past year). Incidence rate of HIV transmission was calculated as the number of phylogenetically linked HIV infections that occurred during eligible couple-years of follow-up divided by eligible couple-years of follow-up. Two-sided 95% CIs for the incidence rate of transmission were calculated using exact Poisson methods. FINDINGS: Between Sept 15, 2010, and July 31, 2017, 972 gay couples were enrolled, of which 782 provided 1593 eligible couple-years of follow-up with a median follow-up of 2·0 years (IQR 1·1-3·5). At baseline, median age for HIV-positive partners was 40 years (IQR 33-46) and couples reported condomless sex for a median of 1·0 years (IQR 0·4-2·9). During eligible couple-years of follow-up, couples reported condomless anal sex a total of 76 088 times. 288 (37%) of 777 HIV-negative men reported condomless sex with other partners. 15 new HIV infections occurred during eligible couple-years of follow-up, but none were phylogenetically linked within-couple transmissions, resulting in an HIV transmission rate of zero (upper 95% CI 0·23 per 100 couple-years of follow-up). INTERPRETATION: Our results provide a similar level of evidence on viral suppression and HIV transmission risk for gay men to that previously generated for heterosexual couples and suggest that the risk of HIV transmission in gay couples through condomless sex when HIV viral load is suppressed is effectively zero. Our findings support the message of the U=U (undetectable equals untransmittable) campaign, and the benefits of early testing and treatment for HIV. FUNDING: National Institute for Health Research.


Related Papers

No related papers found

Powered by citation graph analysis